Is excision repair cross-complementation Group1 expression a biological marker in nasopharynx carcinoma?

Basit Öğe Kaydı
dc.contributor.authorAksoy, Asude Orhan
dc.contributor.authorElkıran, Emin
dc.contributor.authorHarputluoǧlu, Hakan
dc.contributor.authorDağlı, Adile Ferda
dc.contributor.authorIşıkdoğan, Abdurrahman
dc.contributor.authorUrakçı, Zuhat
dc.date.accessioned2021-09-15T10:46:26Z
dc.date.available2021-09-15T10:46:26Z
dc.date.issued2019en_US
dc.departmentDicle Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıklar Ana Bilim Dalıen_US
dc.descriptionPMID:31169219
dc.description.abstractObjective: To determine the prognostic value of excision repairs cross-complementation group1 (ERCC1) gene in cases with nasopharyngeal carcinoma (NPC) treated with platinum-containing chemotherapy (PCT). Subjects and Methods: The present study was included 33 cases in local advanced stage with NPC. ERCC1 expression was evaluated by using immunohistochemical staining in biopsy specimens. We evaluated the relationship between the degree of ERCC1 expression and clinicopathological features, response to therapy, survival rates in cases with NPC, retrospectively. Results: ERCC1 expression was not observed in 5 (15.15%) of all cases. Thirteen (39.9%) cases weakly positive (+1, +2) and 15 (45.5%) cases of all them were rather strongly positive (+3). There was no statistically significant difference between the degree of ERCC1 expression and clinicopathological features, response to treatment, survival rates (P > 0.05) in cases with NPC. Conclusions: ERCC1 expression has no predictive value for survival in cases locally advanced stage with NPC. Evaluation of ERCC1 expression is not appropriate with a biomarker to detect cases who can benefit from PCT in NPC.en_US
dc.identifier.citationAksoy, A. O., Elkıran, E., Harputluoǧlu, H., Dağlı, A. F., Işıkdoğan, A. ve Urakçı, Z. (2019). Is excision repair cross-complementation Group1 expression a biological marker in nasopharynx carcinoma?. Journal of Cancer Research and Therapeutics, 15(3), 550-555.en_US
dc.identifier.doi10.4103/0973-1482.206865
dc.identifier.endpage555en_US
dc.identifier.issn0973-1482
dc.identifier.issue3en_US
dc.identifier.pmid31169219
dc.identifier.scopus2-s2.0-85067062546
dc.identifier.scopusqualityQ3
dc.identifier.startpage550en_US
dc.identifier.urihttps://www.cancerjournal.net/showcaptcha.asp?RedirectUrl=article&issn=0973-1482;year=2019;volume=15;issue=3;spage=550;epage=555;aulast=Aksoy
dc.identifier.urihttps://hdl.handle.net/11468/7612
dc.identifier.volume15en_US
dc.identifier.wosWOS:000470851300017
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorIşıkdoğan, Abdurrahman
dc.institutionauthorUrakçı, Zuhat
dc.language.isoenen_US
dc.publisherWolters Kluwer Medknow Publicationsen_US
dc.relation.ispartofJournal of Cancer Research and Therapeutics
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectExcision repair cross-complementation group1en_US
dc.subjectNasopharyngeal carcinomaen_US
dc.subjectPlatinum resistanceen_US
dc.subjectSurvivalen_US
dc.titleIs excision repair cross-complementation Group1 expression a biological marker in nasopharynx carcinoma?en_US
dc.titleIs excision repair cross-complementation Group1 expression a biological marker in nasopharynx carcinoma?
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Is excision repair cross‑complementation.pdf
Boyut:
1.18 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Makale Dosyası
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Dahili Tıp Bilimleri Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu